Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Novartis receives an exclusive license to an undisclosed discovery target

Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio

Read more at globenewswire.com